Skyrizi Launch Skyrockets, Boosting AbbVie Hopes For Humira Successors

 
• By Joseph Haas

AbbVie’s balancing act sees Skyrizi/Rinvoq launches and strong hematologic cancer strength offset the continued erosion of Humira sales outside the US. Rinvoq gets off to a quick start in its US launch.

Pebble tower on the seaside - Image
AbbVie is successfully balancing Humira's biosimilar erosion with new brand growth

More from Earnings

More from Business